Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Amazon Explores AI Content Marketplace With Media Publishers 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
PLYMOUTH, Minn., Nov. 14, 2017 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering minimally invasive ENT procedures, today announced the Company plans to participate in two upcoming investor conferences.
- November 28, 2017 at 1:30pm ET, Entellus management is scheduled to present at the 29th Annual Piper Jaffray Healthcare Conference in New York, NY. Interested parties can access the live and archived webcast at http://www.entellusmedical.com.
- December 13, 2017, Entellus management plans to participate in the Guggenheim Healthcare Conference.
About Entellus Medical, Inc.
Entellus is a medical technology company focused on delivering superior patient and physician experiences through products designed for less invasive treatments. Entellus products are used for the treatment of adult and pediatric patients with chronic and recurrent sinusitis, patients with nasal airway obstruction, as well as adult patients with persistent Eustachian tube dysfunction. The Entellus platform of products provides safe, effective and easy-to-use solutions intended to enable treatment of patients in more cost-effective sites of care. Entellus’s product lines including the XprESS™ ENT Dilation System, Latera™ Absorbable Nasal Implant, MiniFESS™ Surgical Instruments, XeroGel Nasal Dressing and FocESS™ Imaging & Navigation combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the most cost effective and efficient site of care. Entellus is committed to broadening its product portfolio with high-quality and purposeful innovations for the global ENT market.
Contact: Lynn Pieper Lewis
415-937-5402
[email protected]
